Skip to main content

Table 4 Genotype frequencies of NOS polymorphisms among participants in the LHS cohort and their associations with lung function

From: Nitric oxide synthase polymorphisms, gene expression and lung function in chronic obstructive pulmonary disease

Gene

SNP

Genotype

N

Mean ± SE Baseline FEV1(% predicted)

p-value*a

p-value*b

N

Mean ± SE Rate of Decline in FEV1(% predicted)

p-value*a

p-value*b

NOS1

rs41279104

CC

2650 (79%)

78.39 ± 0.17

Referent

0.1424

2602 (79%)

-0.97 ± 0.04

Referent

0.3530

CT

650(19%)

78.84 ± 0.37

0.7688

635 (19%)

-1.02 ± 0.07

0.5332

TT

55 (2%)

79.33 ± 1.19

0.3825

52 (2%)

-1.27 ± 0.26

0.3434

NOS2

rs8078340

GG

2760 (76%)

78.64 ± 0.17

Referent

0.1118

2705 (76%)

-0.96 ± 0.03

Referent

0.1838

AG

794 (22%)

78.28 ± 0.32

0.7166

781 (22%)

-1.03 ± 0.07

0.8221

AA

81 (2%)

77.82 ± 1.00

0.2977

81 (2%)

-1.12 ± 0.20

0.4215

NOS3

rs1800779

AA

1448 (41%)

77.97 ± 0.24

Referent

0.0018

1425 (41%)

-1.05 ± 0.05

Referent

0.3838

AG

1552 (44%)

78.81 ± 0.23

0.8034

1521 (44%)

-0.92 ± 0.05

0.1149

GG

516 (15%)

79.31 ± 0.39

0.0273

504 (15%)

-1.02 ± 0.07

0.7133

  1. *p-values were adjusted for age, sex, and smoking history (pack-years).
  2. ap-value for comparison to the wild type homozygous genotype.
  3. bp-value for the additive model.